Document is current
Any future updates will be listed below
-
Authors
Molero, Patricio https://orcid.org/0000-0002-9287-9635
Ibañez, Angela https://orcid.org/0000-0003-2751-0150
de Diego-Adeliño, Javier https://orcid.org/0000-0001-9708-2441
Ramos-Quiroga, J. Antoni https://orcid.org/0000-0003-1622-0350
García Dorado, Marta https://orcid.org/0000-0001-6972-6131
López Rengel, Paola M. https://orcid.org/0000-0002-2496-8337
Saiz, Pilar A. https://orcid.org/0000-0002-5705-4523
-
Funding
Funding for this research was provided by:
Janssen Cilag SA, Johnson & Johnson Company
- License Information
-
More Information
Article History
Received: 24 December 2024
Accepted: 17 February 2025
First Online: 19 March 2025
Declarations
:
: Patricio Molero reports to have received research grants from the Ministry of Education (Spain), the Government of Navarra (Spain), the Spanish Foundation of Psychiatry and Mental Health and AstraZeneca; he is a clinical consultant for MedAvanteProPhase and Worldwide Clinical Trials Limited, has received lecture honoraria from or has been a consultant for AB-Biotics, Adept Field Solutions, Dialectica, Guidepoint, Janssen, Novumed, Roland Berger, and Scienta, received travel support for taking part in scientific meetings in the last 3 years (air/ground tickets + hotel) from Boston Scientific and Janssen, and has been the principal investigator of several studies supported by Janssen and Novartis about the efficacy and safety of novel pharmacological treatments for depression. Angela Ibañez has received research support from or served as advisor or speaker or for Janssen-Cilag, Lundbeck, Otsuka Pharmaceutical SA, Alter, Rovi, Casen Recordati and Viatris. Javier de Diego-Adeliño has received grants from Instituto de Salud Carlos III (PI23/00469) and the Fundació La Marató de TV3 (202207-31), advisory board and/or speaker’s honorarium from Jonhson&Jonhson, Lundbeck, Pfizer, Neuraxpharm, Esteve, and Amgen. J. Antoni Ramos-Quiroga was on the speakers’ bureau and/or acted as consultant for Biogen, Idorsia, Casen-Recordati, Janssen-Cilag, Novartis, Takeda, Bial, Sincrolab, Neuraxpharm, Novartis, BMS, Medice, Rubió, Uriach, Technofarma and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Idorsia, Janssen-Cilag, Rubió, Takeda, Bial and Medice. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Exeltis, Idorsia, Janssen- Cilag, Neuraxpharm, Oryzon, Roche, Probitas and Rubió. Marta García Dorado and Paola M. López Rengel are full-time employees of Janssen-Cilag S.A., Johnson & Johnson Company. Pilar A. Saiz has been a consultant to and/or has received honoraria or grants from Adamed, Alter Medica, Angelini Pharma, CIBERSAM, Ethypharm Digital Therapy, European Commission, Government of the Principality of Asturias, Instituto de Salud Carlos III, Johnson & Johnson, Lundbeck, Otsuka, Pfizer, Plan Nacional Sobre Drogas, Rovi, Servier, and Viatris España.
: The study was reviewed and approved by the Ethics Committee of Hospital Clínico San Carlos (Madrid, Spain; Reference # 22/656-O_M_NoSP), and written informed consent was obtained from all subjects. The study was conducted in accordance with the declaration of Helsinki.
